Ground Report | New Delhi: Covaxin’s efficacy revealed; Hyderabad-based vaccine maker Bharat Biotech’s final assessment of the capability of the corona vaccine – Covaxin has been completed. It has been found to be 77.8 percent effective against cases with symptoms of Covid-19 and 65.2 percent against new delta variants.
The company gave this information after the completion of the third phase of trials on Saturday. Phase III clinical trials of the vaccine were conducted at 25 locations in India with a situation-based analysis of 130 symptomatic COVID-19 cases reported at least two weeks after the second dose.
The vaccine has been developed in partnership with the Indian Council of Medical Research (ICMR) and the National Institute of Virology, Pune.
Krishna Ella, Chief and Managing Director, Bharat Biotech said, “We are proud to say that India’s innovation will now be available to secure the global population.
Balram Bhargava, Director General, ICMR said that I am happy to share that the covaccine developed by ICMR and BBIL under an effective Public Private Partnership (PPP) has proved to be 77.8 percent effective in India’s largest ever Phase III COVID clinical trials. happened.
Bhargava said that I am happy that Covaccine works well against all forms of SARS-CoV-2. (Covaxin’s efficacy revealed)
According to data published on preprint server medRxiv, the trial – which is said to be India’s largest ever COVID phase 3 clinical trial – was conducted between November 16, 2020 and January 7, 2021 among 25,798 participants who were randomized to the BBV152 or placebo groups; 24,419 received either two doses of BBV152 or placebo at four-week intervals.
The data showed 130 cases of symptomatic infection in a case-driven analysis of 16,973 participants who were followed for two weeks after the second dose. Of these 130 cases, 24 infections occurred in the vaccine group and 106 in placebo recipients, resulting in an overall vaccine efficacy of 77.8 percent.
A high efficacy against severe COVID-19 indicates that cases that require hospitalization and endanger healthcare facilities are markedly lower among the fully vaccinated population, the researchers said. Will be
The researchers also obtained consent to test vaccines that were exposed during clinical trials. A total of 79 variants were reported from 16,973 samples, 18 in the vaccine and 61 in the placebo group. Of the 50 delta (b.1.617.2) positive cases, 13 and 37 participants were in the vaccine and placebo arms, respectively, resulting in a vaccine efficacy of 65.2%. The effectiveness of the kappa (b.1.617.1) version was 90.1%.
Dr Krishna Ella, Chairman and Managing Director, Bharat Biotech said, “The safety profile of Covaxin is now well established due to its extensive 20-year safety track record based on inactivated vaccine technology and Bharat Biotech’s Vero Cell manufacturing platform.” International Limited (BBIL) said in a statement issued on Saturday.